Veracyte, Inc. (VCYT) bonds
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$25.57+1.34 (+5.53%)
Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Veracyte reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Veracyte's 10-K for the period ended Dec 31, 2021
Veracyte's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| Revolving credit facility | $10.00M | – |
| Secured Debt | $25.00M | – |
| Silicon Valley Bank | – | $1 |
| Silicon Valley Bank | $35.00M | – |
See a number that looks wrong?